|
Hypospadias
|
0.370 |
Biomarker
|
disease |
BEFREE |
Another AP-1 superfamily gene, ATF3, could be responsible for some instances of hypospadias in humans.
|
29670181 |
2018 |
|
Hypospadias
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
The SNPs in ESR2 and ATF3 were borderline associated with hypospadias [odds ratios 0.9 (95% confidence interval 0.7-1.0) and 1.2 (95% confidence interval 1.0-1.4), respectively] but in the opposite direction compared with earlier publications.
|
20215396 |
2010 |
|
Hypospadias
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Mastermind-like domain containing 1/chromosome X open reading frame 6 mutation and activating transcription factor 3 variants have been shown to be associated with the incidence of isolated hypospadias.
|
19995686 |
2010 |
|
Hypospadias
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
In addition, ATF3 expression in 1 human fetal penis with and 1 without hypospadias was studied by immunohistochemical analysis.
|
18804813 |
2008 |
|
Hypospadias
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Three common SNPs, spanning a region of about 16 kb in intron 1 of ATF3, are associated with hypospadias.
|
18426833 |
2008 |
|
Hypospadias
|
0.370 |
GeneticVariation
|
disease |
LHGDN |
Activating transcription factor 3: a hormone responsive gene in the etiology of hypospadias.
|
18426833 |
2008 |
|
Hypospadias
|
0.370 |
Biomarker
|
disease |
BEFREE |
ATF3 is involved in the TGF-beta epithelial-mesenchymal signaling pathway, and its involvement in hypospadias suggests that ATF3 plays a role in development of this anomaly as a result of exposure to estrogenic compounds.
|
18001166 |
2007 |
|
Hypospadias
|
0.370 |
Biomarker
|
disease |
CTD_human |
Estradiol upregulates activating transcription factor 3, a candidate gene in the etiology of hypospadias.
|
18001166 |
2007 |
|
Hypospadias
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that ATF3 is up-regulated in the penile skin tissues of boys with hypospadias, suggesting a role for this transcription factor in the development of this abnormality.
|
16306208 |
2005 |
|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
BEFREE |
Our results thus support that ATF3 is a tumor suppressor in prostate cancer.
|
26522727 |
2016 |
|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
BEFREE |
Taken together, our results demonstrate that SUMO modification of ATF3 influences CCND1/2 activity and cellular proliferation of prostate cancer PC3 and DU145 cells and explains at least in part how ATF3 functions to regulate cancer development.
|
23591848 |
2013 |
|
Malignant neoplasm of prostate
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Activating transcription factor 3 (ATF3) is a common mediator of cellular stress response signaling and is often aberrantly expressed in prostate cancer.
|
22665497 |
2012 |
|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
BEFREE |
KAI1 gene is engaged in NDRG1 gene-mediated metastasis suppression through the ATF3-NFkappaB complex in human prostate cancer.
|
21454613 |
2011 |
|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
CTD_human |
Forced ATF3 over expression in a prostate cancer cell line induced cell proliferation and accelerated cell cycle progression from G1 to S-phase.
|
16516039 |
2006 |
|
Malignant neoplasm of prostate
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Our immunohistochemical analysis on prostate cancer specimens revealed that nuclear expression of ATF3 was inversely correlated to Drg-1 expression and positively correlated to metastases.
|
17178897 |
2006 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Our research has aimed to study the effect of ATF3 expression on cardiomyocytes, heart function and glucose homeostasis in an obesity-induced T2D mouse model.
|
28082453 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
ATF3 was highly expressed in the livers of ZDF rats and in human participants with NAFLD and/or T2D.
|
28365312 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.340 |
Biomarker
|
disease |
BEFREE |
The Atf3 gene is associated with the induction of type 2 diabetes and alcohol consumption-induced metabolic impairment and thus may be the major negative regulator for glucose homeostasis.
|
25074928 |
2014 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.340 |
Biomarker
|
disease |
BEFREE |
The unique sterol-independent LDLR repression by organelle stress via ATF3 demonstrated here could be involved in obesity-related hypercholesterolemia, which can lead to insulin resistance and type 2 diabetes.
|
21294679 |
2011 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.340 |
Biomarker
|
disease |
CTD_human |
Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes.
|
16123366 |
2005 |
|
Cardiomyopathies
|
0.320 |
Biomarker
|
group |
BEFREE |
Indoxyl sulfate upregulates the cannabinoid type 1 receptor gene via an ATF3/c-Jun complex-mediated signaling pathway in the model of uremic cardiomyopathy.
|
29203210 |
2018 |
|
Cardiomyopathies
|
0.320 |
Biomarker
|
group |
BEFREE |
ATF3 exerts both local and systemic effects related to T2D-induced cardiomyopathy.
|
28082453 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
Thus, we have identified ATF3 as an important regulator of cisplatin cytotoxicity and that ATF3 inducers in combination with platins are a potential novel therapeutic approach for NSCLC.
|
27659012 |
2016 |
|
Cardiomyopathies
|
0.320 |
Therapeutic
|
group |
CTD_human |
Characterization of the regulatory mechanisms of activating transcription factor 3 by hypertrophic stimuli in rat cardiomyocytes.
|
25136830 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
This suggests that DR5 is modulated by the ATF4-ATF3-CHOP axis in NSCLC after Sirt1/2 inhibition or salermide treatment.
|
21801305 |
2012 |